http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1428426-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23a4e0c875bf1ac2b8a3b76517de6c7d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 |
| filingDate | 1973-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1976-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1428426-A |
| titleOfInvention | Pharmaceutical and diagnostic compositions |
| abstract | 1428426 Sustained release compositions; diagnostic devices PURDUE RESEARCH FOUNDATION 5 June 1973 [9 June 1972] 26662/73 Heading A5B A sustained release medicament formulation with prolonged gastric residence comprises (a) a medicament core and (b) a pharmaceutically acceptable coating on the core comprising a crosslinked polymeric film which comprises a prepolymer crosslinked with a cross-linking agent at a ratio of 8 parts by weight of prepolymer to 0.15 to 4 parts by weight of crosslinking agent, the prepolymer being a copolymer of (i) 20-90 parts by weight of a substituted or unsubstituted unsaturated dicarboxylic acid or acid anhydride having 1 to 3 carbon atoms between the two carboxylic groups, and (ii) 10-80 parts by weight of an alkene of 2 to 6 carbon atoms, styrene or an alkyl vinyl ether in which the alkyl radical contains 1 to 16 carbon atoms, the polymeric film being waterhydratable, water-permeable and swellable in the presence of gastric fluids. A large number of active ingredients are specified as being suitable for use in the medicament core. The core may also be coated with a binary polymeric film including a pharmaceutically acceptable, substantially water-insoluble polymeric component and a pharmaceutically acceptable polymeric component as defined in (b) above. The medicament core may be replaced by a diagnostic device such as a Heidelberg capsule. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8043630-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-767812-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9597338-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4938967-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8945619-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3106984-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-614328-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0156544-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8329215-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7736667-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0156544-A2 |
| priorityDate | 1972-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.